Liquid Chromatography-Tandem Mass Spectrometry Outperforms Fluorescence Polarization Immunoassay in Monitoring Everolimus Therapy in Renal Transplantation
Authors:
- Dirk Jan A R MoesDirk Jan A R Moes
- Rogier R PressRPRogier R Press
- Johan W de FijterJFJohan W de Fijter
- Henk-Jan GuchelaarHGHenk-Jan Guchelaar
- Jan Den HartighJHJan Den Hartigh
- 1 August 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 32 (4) , 413-419
Abstract
There is a need to monitor everolimus blood concentrations in renal transplant recipients as a result of its high pharmacokinetic variability and narrow therapeutic window. However, analytical methods to determine blood concentrations often differ in performance. Therefore, we investigated whether two commonly used therapeutic drug monitoring methods for everolimus were in agreement and to what extent their differences could lead to differences in dosage advice. Six hundred twelve whole blood samples were obtained from 28 adult renal transplant recipients receiving everolimus and prednisolone therapy. These samples included 286 everolimus trough concentrations. The remaining samples were obtained up to 6 hours post everolimus intake and allowed calculation of 84 AUCs0-12h. All samples were analyzed with fluorescence polarization immunoassay (FPIA) on an Abbott TDxFLx analyzer and liquid chromatography-tandem mass spectrometry (LC-MS/MS). Everolimus blood concentrations measured with FPIA and LC-MS/MS were not in agreement. Concentrations determined by FPIA were, on average, 23% higher than concentrations quantified by LC-MS/MS. Moreover, concentrations lower than 15 mug/L or AUC0-12h determined with FPIA could be twofold higher than with LC-MS/MS. This variability can lead to clinically relevant differences in dose adjustment of up to 1.25 mg everolimus despite using a correction factor of 23%. Finally, when trough concentrations were measured with FPIA, higher intrapatient variability was observed compared with the use of LC-MS/MS. LC-MS/MS outperforms FPIA for clinical drug monitoring and intervention of everolimus therapy in adult renal transplant recipients on dual therapy with prednisolone. Specifically, the use of FPIA can lead to clinically relevant differences in everolimus dosage advice and higher intrapatient variability.Keywords
This publication has 20 references indexed in Scilit:
- Minimization of Maintenance Immunosuppression Early After Renal Transplantation: An Interim AnalysisTransplantation, 2009
- Robust, High-Throughput LC-MS/MS Method for Therapeutic Drug Monitoring of Cyclosporine, Tacrolimus, Everolimus, and Sirolimus in Whole BloodTherapeutic Drug Monitoring, 2009
- Comparison between a liquid chromatography‐tandem mass spectrometry assay and a fluorescent polarization immunoassay to measure whole blood everolimus concentration in heart and renal transplantationsJournal of Clinical Laboratory Analysis, 2008
- Recent development in application of high performance liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressantsJournal of Immunological Methods, 2008
- Comparison of the Innofluor® certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantationClinical Biochemistry, 2006
- Clinical Pharmacokinetics of EverolimusClinical Pharmacokinetics, 2004
- Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporineClinical Pharmacology & Therapeutics, 2001
- Bioanalytical Method Validation—A Revisit with a Decade of ProgressPharmaceutical Research, 2000
- Measuring agreement in method comparison studiesStatistical Methods in Medical Research, 1999
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986